These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1225 related articles for article (PubMed ID: 26294295)

  • 21. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
    van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
    J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas.
    Wu HB; Wang QS; Wang MF; Li HS; Zhou WL; Ye XH; Wang QY
    Nucl Med Commun; 2010 Mar; 31(3):195-200. PubMed ID: 20009963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
    Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
    J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial experience of integrated PET/MR mammography in patients with invasive ductal carcinoma.
    Kong EJ; Chun KA; Bom HS; Lee J; Lee SJ; Cho IH
    Hell J Nucl Med; 2014; 17(3):171-6. PubMed ID: 25397622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
    Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
    Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rate of Distant Metastases on 18F-FDG PET/CT at Initial Staging of Breast Cancer: Comparison of Women Younger and Older Than 40 Years.
    Lebon V; Alberini JL; Pierga JY; Diéras V; Jehanno N; Wartski M
    J Nucl Med; 2017 Feb; 58(2):252-257. PubMed ID: 27587709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI; Lee SW; Jeong SY; Chae YS; Lee WK; Ahn BC; Lee J
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
    Taneja S; Jena A; Goel R; Sarin R; Kaul S
    Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
    King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
    Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Sahin E; Kus T; Aytekin A; Uzun E; Elboga U; Yilmaz L; Cayirli YB; Okuyan M; Cimen V; Cimen U
    J Nucl Med; 2024 Apr; 65(4):512-519. PubMed ID: 38485276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
    Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.